mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13449
Abstract: Multiple prognostic biomarkers, including circulating tumor cell (CTC) counts, exist in metastatic castration-resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy screening test-sequencing system… read more here.
Keywords: dna; cell free; mcrpc patients; aneuploidy score ... See more keywords
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Sign Up to like & getrecommendations! Published in 2021 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-021-00344-1
Abstract: BACKGROUND In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, enzalutamide, and radium-223) were introduced in the… read more here.
Keywords: mcrpc; subgroup; mcrpc patients; prostate cancer ... See more keywords
Abstract 6698: Combinatorial genomic and epigenomic cell-free DNA analysis of high-risk metastatic castration resistant prostate cancer reveals prognostic liquid biopsy signatures
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6698
Abstract: Background: Androgen receptor signaling inhibitors (ARSI) such abiraterone and enzalutamide have significantly improved clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients. However, patients with genomic alterations in the androgen receptor (AR) and its enhancer… read more here.
Keywords: enhancer; cell free; mcrpc patients; high risk ... See more keywords
Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval
Sign Up to like & getrecommendations! Published in 2024 at "EJNMMI Research"
DOI: 10.1186/s13550-024-01143-0
Abstract: The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high disease volume and rapid progression. This retrospective analysis evaluated… read more here.
Keywords: week; treatment; week group; psa ... See more keywords
Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5070
Abstract: 5070Background: Prior response to A or E does not predict sensitivity to E following A or A following E. The detection of AR-V7 predicts insensitivity to either drug, but identifies only a portion ... read more here.
Keywords: mcrpc patients; outcomes mcrpc; ctc subtype; baseline ctc ... See more keywords
Early changes in PSA and association with outcomes in mCRPC patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5063
Abstract: 5063Background: Declines in prostate specific antigen (PSA) levels at 12-weeks are currently used to evaluate treatments response in metastatic castration resistant prostate cancer (mCRPC). Early P... read more here.
Keywords: association outcomes; outcomes mcrpc; mcrpc patients; psa association ... See more keywords
cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.256
Abstract: 256Background: Alterations in Wnt signaling have been shown to play a role in the development of castrate resistant prostate cancer. Cell free DNA (cfDNA) isolated from patient plasma can provide a non-invasive way to further… read more here.
Keywords: wnt signaling; mcrpc patients; analysis mcrpc; cfdna analysis ... See more keywords
Combination of carboplatin (AUC4) and cabazitaxel (25 mg/m2) in mCRPC patients not or no longer responding to cabazitaxel monotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.371
Abstract: 371Background: Cabazitaxel monotherapy is a second line treatment option for mCRPC patients. However, not all patients have a PSA response on this treatment, while a proportion of patients develop resistance during cabazitaxel treatment. Platinum drugs… read more here.
Keywords: combination; mcrpc patients; cabazitaxel monotherapy; cabazitaxel ... See more keywords
Plasma-based exploratory biomarker analysis to evaluate GT0918 in a phase I/II study in mCRPC patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.279
Abstract: 279 Background: GT0918, a novel potent androgen receptor antagonist, has been evaluated in a ph 1/2 study in mCRPC patients for its safety and efficacy. Here using patient plasma samples, we explored cell-free DNA &… read more here.
Keywords: mcrpc patients; treatment; study mcrpc; gt0918 ... See more keywords
Baseline PSMA PET/CT as a predictive biomarker for toxicity and patient-reported outcomes in mCRPC patients undergoing 177Lu-PSMA radioligand therapy.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e17058
Abstract: e17058 Background: The phase III VISION trial demonstrated that 177Lu-PSMA-617 (PSMA-RLT) prolonged overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). Common side effects of PSMA-RLT include xerostomia, bone pain, and myelosuppression. The objective… read more here.
Keywords: patient reported; time; toxicity; reported outcomes ... See more keywords
Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.210
Abstract: 210 Background: Routine germline and somatic testing is recommended by professional guidelines as standard of care for all mCRPC patients since the approvals of poly ADP ribose polymerase inhibitors (PARPi) for treatment in those with… read more here.
Keywords: germline somatic; treatment; mcrpc; real world ... See more keywords